MGX (Metagenomi Therapeutics) Common Stock: $0.00 Mil (As of Mar. 2026)


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.26
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Common Stock?

Metagenomi Therapeutics MGX -2.48% 10 Common Stock is $0.00 Mil as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Metagenomi Therapeutics's quarterly common stock stayed the same from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) and stayed the same from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Metagenomi Therapeutics's annual common stock increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then stayed the same from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Metagenomi Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics Common Stock Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
0.57 2.54 0.00 0.00 0.00

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.00 Mil mean?
Metagenomi Therapeutics (MGX) has a Common Stock of $0.00 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' Common Stock too high?
Metagenomi Therapeutics' current Common Stock is $0.00 Mil. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Common Stock compare to KALA and HYPD?
Metagenomi Therapeutics' Common Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current Common Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current Common Stock of $0.00 Mil. The current Common Stock is $0.00 Mil. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Common Stock is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price